CS Paper Radar

BiGSyn: A Bi-Level Heterogeneous Graph Contrastive Learning Framework for Interpretable Drug Synergy Prediction

Senquan Wang, Hui Fang, Haoran Nan, Xingwei Wang, Qiang He

cs.AI ·submitted 2026-11-16 06:28 UTC · v1
publishedbenchmark

Abstract

Drug combination therapy has become a mainstream of modern medicine, with the potential to enhance efficacy, reduce toxicity, and overcome drug resistance. However, identifying synergistic drug combinations remains challenging, as it requires modeling complex interactions across multiple biological scales---from atom-level molecular structures to entity-level relations in biological networks. Existing approaches typically model these levels in isolation, overlooking complementary signals and long-range dependencies. To address these limitations, we propose BiGSyn, a Bi-level heterogeneous Graph contrastive learning framework for drug Synergy prediction. Specifically, BiGSyn leverages heterogeneous graph transformers to extract high-order dependencies from molecular graphs and biological networks, and introduces a bi-level contrastive learning objective to bridge the cross-level semantic gap. Extensive experiments on two benchmark datasets show that BiGSyn consistently outperforms state-of-the-art baselines. Moreover, its attention mechanism highlights key molecular substructures and biological interactions driving synergy, providing interpretable insights.

Comment
2026 IEEE International Conference on Data Mining (ICDM 2026)

Closest papers

Nearest neighbours by meaning across the whole index.

VINCENT: Validated Interaction Network for Cross-drug Explanation of Therapeutics

cs.LG cs.AI ·2026-08-26 ·Fan-Sheng Chuang, Xuchen Li, Yujing Bian, Kaixiong Zhou
similarity 0.73
Abstract · 18 pages, 4 figures

Drug synergy prediction estimates whether two drugs produce a stronger joint effect than expected from their individual activities. For drug combination discovery, a single synergy score is often not enough: researchers also need to know which molecular regions jointly drive the prediction. We study motif-pair synergy explanation, which identifies pairs of chemically coherent regions, one from each drug, that jointly contribute to predicted synergy. Existing interpretable synergy models expose atom- or substructure-level signals, but their explanations are built into the predictor architecture, and none validates cross-drug region scores under repeated perturbations or feeds that evidence back to refine the explanation. A reliable motif-pair explanation should instead be chemically coherent, perturbation-stable, and aligned with predictor behavior. We introduce VINCENT (Validated Interaction Network for Cross-drug Explanation of Therapeutics), a post-training framework for a fixed interaction-aware synergy predictor. VINCENT extracts atom-pair evidence from attention and gradient signals, groups atoms into chemically coherent motifs, and validates candidate motif pairs through repeated local perturbations. The validated evidence is fed back to refine motif assignments, yielding explanations that satisfy these three criteria. On a 25-pair literature-annotated subset, VINCENT achieves a mean motif recall of 0.826 (95% CI: 0.78-0.87), compared with 0.49-0.66 for baselines. Across all 71 test pairs, its validated interaction scores yield a TP/TN separation of 3.36. These results show that closed-loop perturbation validation recovers literature-supported molecular regions more accurately than existing alternatives while producing cross-drug interaction scores that better reflect predictor behavior.

0.16

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

cs.LG cs.AI ·2026-10-19 ·Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
published similarity 0.72
Abstract · 20 pages, 7 figures

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest \(r_m^2\) of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7\% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.

0.31

Benchmarking graph-based models for in-silico toxicity prediction in drug discovery

cs.LG q-bio.BMq-bio.QM ·2026-09-29 ·Noel Suarez-Barro, Manuel Lama, Juan C. Vidal
code/data similarity 0.72
Abstract

Drug discovery is a costly and high-risk process, where toxicity-related failures remain a major cause of attrition in both preclinical and clinical stages. As a result, accurate early prediction of chemical toxicity is essential to reduce downstream costs and improve compound prioritization. In this context, graph deep learning (GDL) has emerged as a powerful paradigm for toxicity prediction, leveraging molecular graph representations to learn directly from chemical structure with improved expressivity over traditional approaches. Despite the growing number of proposed models, current literature-based comparisons are often difficult to interpret due to inconsistencies in datasets, preprocessing pipelines, and evaluation protocols. To address this limitation, we introduce a unified and standardized benchmarking framework for GDL-based toxicity prediction. We systematically evaluate more than 20 representative approaches under consistent experimental conditions and across multiple datasets and partitioning strategies, enabling a fair and reproducible comparison of model performance. In addition, we complement this empirical study with a structured literature analysis to contextualize existing methodological trends and performance claims. Our results provide a clearer and more reliable assessment of the current state of the field, highlighting both the strengths and limitations of existing graph-based approaches. To support transparency and reproducibility, we release our benchmarking framework as open-source software https://gitlab.citius.gal/noel.suarez/benchtox, allowing the community to evaluate and compare models under consistent conditions.

0.24

MoTIF-X: A Multimodal Tokenized Framework for Interpretable and Extensible Molecular Representation Learning

cs.LG ·2026-09-29 ·Linqing Mo, Jiayu Zhou, Bin Chen
code/data similarity 0.69
Abstract · 5 figures. Supplementary material is available as an ancillary file. Code: https://github.com/Bin-Chen-Lab/Motif-X

Molecular representation learning is central to computer-aided drug discovery. Molecular graphs, SMILES strings, and 3D conformations provide complementary structural information, yet many multimodal approaches encode these views independently and align them only at a later stage, limiting fine-grained cross-modal interaction and substructure-level interpretability. To address these limitations, we introduce MoTIF-X, a motif-centered framework that uses graph-grounded chemical motifs as shared anchors for multimodal integration and interpretation. Its first pretraining stage learns motif representations through hierarchical contrastive learning across atomic, motif, and molecular scales. The second stage contextualizes these representations with SMILES and torsion-angle tokens through multimodal masked token modeling. After pretraining on drug-like molecules with multiple conformers, MoTIF-X achieved the lowest mean absolute error on all nine OpenADMET ExpansionRx endpoints and the best overall performance among the evaluated methods. Significance analyses supported its advantage in the vast majority of endpoint-baseline comparisons after multiple-testing correction. Ablation studies supported the complementary contributions of motif-token contextualization, multimodal integration, and two-stage pretraining. Beyond molecular properties, the framework extended to drug-target interaction prediction, achieving the best average classification performance across the evaluated benchmarks and generalizing to an external drug-cold-start dataset without additional fine-tuning. Its motif-centered design also enabled substructure-level interpretation: higher motif attribution scores were associated with larger experimentally measured activity shifts. Together, these findings support MoTIF-X as a transferable and interpretable framework for molecular modeling.

0.23

Fragment-Level Graph Encoding for Interpretable Molecular Property Prediction

cs.LG stat.ML ·2026-10-21 ·Rafael Lopes Almeida, Ina Pöhner
publishedcode/data similarity 0.68
Abstract · 12 pages, 3 figures, 6-page appendices, to be published in Proceedings of the 8th Northern Lights Deep Learning Conference (NLDL), 2027. For…

Graph neural networks (GNNs) are among the standard tools for molecular property prediction, but the atom-level explanations of their predictions are hard for medicinal chemists to act on. We propose a change of input representation rather than a new model: molecules are encoded as fragment-level graphs from BRICS decomposition, where each node is a synthetically meaningful fragment whose features are the element-wise sum of its atoms' features. Because only the representation changes, any message-passing GNN and any post-hoc attribution method produces explanations at the resolution of functional groups instead of single atoms. Across four architectures, four prediction tasks, and two explainers under scaffold splits, fragment-level encoding matches atom-level test accuracy on roughly five-fold smaller graphs. Integrated-Gradients attributions recover known pharmacophores above chance on two enzyme targets, namely BACE at 1.5 times the chance rate, and PTR1 at 3.2 times. A like-for-like comparison against an aggregated atom-level baseline shows that post-hoc aggregation is not a stable substitute: its BACE hit rate range both exceeds and falls below the fragment model's hit rate depending on two arbitrary aggregation choices, whereas fragment-level training yields a single convention-free attribution at no predictive cost. The code is available at: https://github.com/4D-Lab/frame

0.36

DrugReason: Dynamic Multi-View Reasoning over Knowledge Graph and Language Evidence for Drug Repurposing

cs.LG cs.AI ·2026-09-06 ·Zijie Liu, Hongxuan Li, Zhen Tan, Jinhao Duan, Baixiang Huang +3 more
top venuecode/data similarity 0.68
Abstract · EMNLP 2026 Main Conference Code: https://github.com/jesseliu0913/DrugReason

Drug repurposing aims to identify new therapeutic uses for existing compounds and, compared with de novo drug discovery, offers a faster and more cost-effective path to clinical translation. However, the space of candidate drug-disease pairs is enormous and their underlying relationships often depend on complex multi-hop biological mechanisms, making it difficult to reliably predict which pairs represent true therapeutic relationships. Existing approaches tackle this from two directions: knowledge graph-based methods organize curated biomedical evidence into structured relational networks for grounded multi-hop reasoning, while LLM-based methods leverage pretrained knowledge to generate flexible mechanistic rationales. Yet neither is sufficient alone - KGs are confined to observed graph structure while LLMs lack factual grounding and risk hallucination. To address this gap, we propose DrugReason, a multi-view reasoning framework that integrates grounded KG reasoning with LLM-generated mechanistic inference for drug repurposing. DrugReason adaptively routes diverse reasoning paths to specialized experts conditioned on the query context, while a cross-expert distillation objective enables knowledge sharing without sacrificing expert specialization. Experiments on PharmaDB, DDInter, and DrugBank show that DrugReason improves average performance over strong single-view reasoning baselines and achieves competitive or superior results compared with graph-based alternatives, while providing interpretable routing-based predictions.

0.53

Bison: Cross-Dataset Learning for Unseen-Compound Perturbation Prediction

cs.LG cs.AI ·2026-09-26 ·Yunfan Liu, Kasra Ghorbani, Yufei Huang, Zicheng Liu, Jiangbin Zheng +4 more
benchmark similarity 0.68
Abstract

Predicting transcriptional responses to unseen compounds is limited by fragmented chemical coverage and heterogeneous experimental platforms and gene panels. To assess molecular generalization across these settings, we build on Chem-PerturBridge to benchmark eight datasets with 16,771 compounds, withholding test compounds from every training dataset. This comparison reveals that high overall response agreement can coexist with weak prediction of drug-specific differences, despite reproducible signals across repeated measurements. To exploit complementary chemical supervision while targeting these differences, we introduce Bison: a shared gene representation connects native panels, while two discrete diffusion models compose context-dependent responses with molecular deviations learned through matched drug-contrast supervision. A single Bison model jointly trained across all eight datasets achieves the highest mean overall-response and drug-contrast Pearson correlations on the full benchmark in comparison with 11 methods trained independently per dataset. Compared with dataset-specific training of the same architecture, joint training increases mean drug-contrast correlation by 27.4\%, with gains across all eight datasets and improvements in overall response prediction. These results demonstrate how matched drug contrasts turn complementary screens into shared molecular supervision for unseen-drug response prediction while preserving native gene measurements.

0.14

SMILESGNN: Interpretable Clinical Toxicity Prediction via SMILES-Graph Cross-Attention Fusion

cs.LG cs.AI ·2026-09-23 ·Quang Minh Nguyen, Thuy Quynh Nguyen, Duc Minh Le, Ho Nhat Minh Nguyen, Thanh Long Dai Doan +1 more
published similarity 0.67
Abstract

Drug toxicity prediction is critical for reducing late-stage attrition in drug discovery, yet remains challenging due to severe class imbalance, scaffold-based generalization, and the clinical need for interpretable predictions. Single-modality approaches-SMILES Transformers or graph neural networks capture complementary aspects of molecular structure, while sequence-only models cannot directly provide graph-attributed explanations. We present SMILESGNN, a multimodal architecture that fuses a SMILES Transformer encoder and a GATv2 graph encoder via cross-attention, and SMILESGNN-PT, a variant using a ChemBERTa-2 pretrained backbone. The design retains an explicit graph branch within the predictive pipeline, supporting GNNExplainer-based analysis of substructures associated with toxic predictions. On ClinTox, SMILESGNN achieves AUC-ROC 0.987 and F1 0.906 with only 0.4M parameters, performing competitively with a strong SMILESTransformer and a larger ChemBERTa-2/GATv2 concat-fusion baseline. On Tox21 (12 tasks), SMILESGNN-PT obtains mean AUC-ROC 0.750, comparable to ChemBERTa-2 alone and the same-backbone concat-fusion baseline. Overall, the results suggest that cross-attention is a practical fusion alternative that preserves competitive predictive performance while enabling graph-based interpretability support.

0.25